Results 91 to 100 of about 811,174 (190)
Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
Early-phase clinical trials of Bruton’s tyrosine kinase (BTK) degraders have demonstrated efficacy in patients with BTK inhibitor-resistant chronic lymphocytic leukemia (CLL). How clinical resistance to BTK degraders arises is unknown.
Jahan Rahman +75 more
core +1 more source
Introduction: Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic tyrosine kinase. Btk plays a crucial role in the BCR signaling, essential for B-cell development, and Btk has been recognized as a validated therapeutic target for ...
Wataru Kawahata +5 more
core +1 more source
ABSTRACT Introduction BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non‐overlapping mechanism but is limited by toxicity.
Steven M. Bair +11 more
wiley +1 more source
BTK (Bruton’s tyrosine kinase) has become a key therapeutic target across several hematologic diseases, beginning with its original use in CLL/SLL.
Andrea Duminuco +9 more
doaj +1 more source
This study characterized biofilm‐forming bacterial strains Pseudomonas aeruginosa MD3 and Bacillus toyonensis LD07 immobilized on sugarcane bagasse. This highly porous bio‐product demonstrated exceptional phenotypic plasticity and robust bioremediation efficacy, achieving 99% chlorpyrifos degradation at 4500 ppm.
Le Thi Nhi‐Cong +6 more
wiley +1 more source
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Bruton’s tyrosine kinase (BTK) is a key signaling molecule involved in both hematological malignancies and solid tumors. In B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), BTK mediates B-cell receptor ...
Zahraa Qusairy, Miran Rada
doaj +1 more source
Economic Burden of Chronic Lymphocytic Leukaemia in Australia
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao +4 more
wiley +1 more source
ABSTRACT Proliferative Kidney Disease (PKD) is a severe parasitic disease of salmonids caused by the malacosporean endoparasite Tetracapsuloides bryosalmonae. In the fish intermediate host, the parasite is disseminated via the circulatory system and ultimately reaches the kidney, where it matures before releasing infective spores into the environment ...
Céline Möckli +4 more
wiley +1 more source
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Although covalent and non-covalent Bruton tyrosine kinase inhibitors (BTKi) have extended clinical benefit to relapsed/refractory (R/R) and BTKi-resistant chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), there remains an unmet need for ...
Pritika Sharma, Heng Jiang, Delong Liu
doaj +1 more source

